It is now appreciated that many mammalian species encode factors conferring resistance to retroviral infections. Some, such as the APOBEC3 family of cytidine deaminases, modify minus strand viral DNA during reverse transcription, resulting in either its degradation or its integration into host chromosomal DNA as a hypermutated provirus. The deleterious activities of APOBEC3G are countered by lentiviral Vif proteins, which prevent the encapsidation of APOBEC3G into nascent virions. The sensitivity of APOBEC3G from different animal species to the Vif proteins expressed by different viruses varies widely. For example, while HIV-1 Vif can potently suppress human APOBEC3G, it is not effective against rhesus monkey APOBEC3G, explaining in part, the restriction of HIV-1 replication in macaque cells. Another recently described restriction factor, TRIM5 alpha, targets incoming viral capsids and blocks retroviral replication in a species specific manner. For example, TRIM5 alpha from rhesus macaques potently suppresses HIV-1 but not SIV infectivity in monkey cells. Although its mechanism of action is still unclear, TRIM5 alpha restriction is thought to affect virus uncoating, thereby blocking subsequent steps in the replication cycle. ? ? HIV-1 derivatives have been constructed, which carry only the SIVmac239 vif gene and a short seven amino acid segment from SIV gag corresponding to the HIV-1 CypA-binding loop. Molecularly cloned viruses bearing these two SIV regions are able to establish spreading infections in a cynomolgus monkey (CyM) T cell line and CD8 depleted PBMCs from pig-tailed macaques (PtM) and rhesus monkeys (RhM). These results indicate that the incorporation of two SIV gene segments into the HIV-1 genome can effectively counter two known species specific restriction factors that block virus replication in monkey cells. They raise the possibility of generating HIV-1 derivatives, containing all of its structural proteins, and capable of infecting macaque monkeys.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000998-01
Application #
7592349
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2007
Total Cost
$2,872,207
Indirect Cost
City
State
Country
United States
Zip Code
Kubo, Makoto; Nishimura, Yoshiaki; Shingai, Masashi et al. (2009) Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J Virol 83:7099-108
Fauci, Anthony S; Johnston, Margaret I; Dieffenbach, Carl W et al. (2008) HIV vaccine research: the way forward. Science 321:530-2
Lafont, Bernard A P; McGraw, Christopher M; Stukes, Sabriya A et al. (2007) The locus encoding an oligomorphic family of MHC-A alleles (Mane-A*06/Mamu-A*05) is present at high frequency in several macaque species. Immunogenetics 59:211-23
Nishimura, Yoshiaki; Igarashi, Tatsuhiko; Buckler-White, Alicia et al. (2007) Loss of naive cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques. J Virol 81:893-902
Kamada, Kazuya; Igarashi, Tatsuhiko; Martin, Malcolm A et al. (2006) Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A 103:16959-64